TY - JOUR
KW - Administration, Inhalation
KW - Patient Acceptance of Health Care
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
KW - chronic obstructive pulmonary disease
KW - exacerbations
KW - general practice
KW - healthcare utilization
KW - Maintenance therapy
AU - L. Sansbury
AU - D. Lipson
AU - C. Bains
AU - G. Anley
AU - K. Rothnie
AU - A. Ismaila
AD - Value Evidence and Outcomes, Epidemiology, R&D Global Medical, GlaxoSmithKline, Research Triangle Park, NC, USA.
Respiratory Clinical Sciences, GlaxoSmithKline, Collegeville, PA, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, Uxbridge, UK.
UK Health Outcomes, GlaxoSmithKline, Uxbridge, UK.
Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
AN - 35264848
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC8901413
DO - 10.2147/copd.s336158
DP - NLM
ET - 2022/03/11
LA - eng
N1 - 1178-2005
Sansbury, Leah B
Lipson, David A
Orcid: 0000-0001-6732-4593
Bains, Chanchal
Anley, Glenn A
Rothnie, Kieran J
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Journal Article
Observational Study
Int J Chron Obstruct Pulmon Dis. 2022 Mar 3;17:415-426. doi: 10.2147/COPD.S336158. eCollection 2022.
PY - 2022
SN - 1176-9106 (Print)1176-9106
SP - 415
EP - 426
T2 - Int J Chron Obstruct Pulmon Dis
TI - Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
VL - 17
ER -